Drug Approval | April 26, 2022
ZyCoV-D two-dose vaccine receives Emergency Use Approval from DCGI
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
Both companies have been selected for stand-by production by German government
Makrolon polycarbonate is key to needle-free injections that can stand up to sterilization
The award also follows GenScript's recognition at the Korea Bioprocessing Excellence Awards in 2021 for the "Best Contract Development and Manufacturing Organization Award".
Novel tool bypasses plasmid-based expression to increase stability and significantly reduce development time for a variety of synthetic biotechnology products
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
The vaccine will be priced at Rs. 265 per dose and the applicator being offered at Rs. 93 per dose excluding GST
The three doses of ZyCoV-D are to be administered 28 days apart. The vaccine was given emergency use authorisation (EUA) by the Indian drug regulator on August 20
Subscribe To Our Newsletter & Stay Updated
